Omidubicel currently has an FDA Breakthrough Designation which is "process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint"
Basically, this means that Omidubicel has so much potential, that the FDA wants to accelerate the approval process.